Phase II Randomized, Double-blind, Placebo-controlled, Two-arm Study to Evaluate the Safety and Efficacy of Erlotinib in the Treatment of Moderate to Severe Psoriasis
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2014
At a glance
- Drugs Erlotinib (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- 12 May 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 13 Apr 2011 Planned End Date changed to 1 Jun 2013, according to ClinicalTrials.gov record..
- 13 Apr 2011 Planned initiation date changed to 1 Jun 2011, according to ClinicalTrials.gov record.